Gyre Therapeutics Releases Q1 2026 Financial Results

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

GYRE|EPS -$0.10|Rev $22.5M|Net Loss $9.9M

Gyre Therapeutics, Inc. (GYRE) reported an adjusted loss of $0.10 per share for the first quarter of 2026, as the pharmaceutical company continues developing its pipeline of anti-inflammatory and anti-fibrotic treatments for organ fibrosis. Revenue totaled $22.5M for the quarter, up 1.8% from the $22.1M recorded in Q1 2025. The bottom line showed an adjusted net loss of $4.2M.

The company’s flagship product ETUARYTM (pirfenidone) generated $21.0M in revenue during the period, though that figure was down 3.2% year-over-year. The small-molecule therapy remains the dominant driver of Gyre’s commercial performance as the company works to expand its portfolio of fibrosis-targeting treatments.

Management provided full-year guidance calling for revenue of $100.5M to $111.0M, signaling expectations for acceleration beyond the modest quarterly growth rate. The pharmaceutical developer faces the twin challenges of maintaining its existing commercial product while advancing earlier-stage candidates through clinical development.

Wall Street maintains a favorable view of the fibrosis specialist, with analyst consensus standing at 5 buy ratings, 1 hold, and 0 sell recommendations. The shares trade on the NASDAQ under the ticker GYRE.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.